Please assess the completion status of the following clinical trial:

Trial Title: Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Parent/guardian (legally authorized representative) has given voluntary written consent to the subject's participation after being fully informed of the purpose, methods, risks, and benefits of the study.~* Male and female children who have completed the primary 3 doses of JEV in the KD287-BR-CT-301study.~* Male and female children reaching at least 6 years of age on the day of booster dosing of JEV.~* Male and female children who are identified to be healthy based on physical examination and medical history.~Exclusion Criteria:~* Children who have acute febrile illness with tympanic temperature of ≥38.0 ℃ on the day of booster dosing of JEV.~* Children who have moderate or severe acute disease (regardless of fever).~* Children who have history of encephalitis, encephalopathy, cerebromeningitis, or convulsion.~* Children who have received JEV (including live JEV) other than the investigational products administered in the KD287-BR-CT-301study.~* Children who have had fever (≥ 40 °C) or systemic allergy within 48 hours after vaccination.~* Children who have shown anaphylactic reaction to the investigational products administered in the KD287-BR-CT-301study or who are likely to be allergic to the ingredients of the investigational product.~* Children who have been diagnosed with immunodeficiency such as acquired immune deficiency or who have family history of immunodeficiency.~* Children who have received other vaccines within 28 days before booster dosing of JEV (vaccines to be administered according to the national vaccination program.~* Children who have received immunosuppressive thera-py within 28 days before booster dosing of JEV.~* There is a possibility that immune globulin preparations has not been excreted enough on the day of booster dosing of JEV if children have received such a product.~* Children who are currently participating or planning to participate in other clinical stud-ies during the study period.~* Other ineligible conditions judged at the discretion of principal investigators or subinvestigators.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 7 Years
- Healthy Volunteers: t

Study Arms:
- Japanese encephalitis vaccine (Type: OTHER): After reconstitution with 0.7 mL of the provided diluent, 0.5-mL dose,SC

Based on this trial design, predict the completion outcome and termination type (if applicable).